Emmaus Life Sciences Inc. has entered into an Exchange Agreement with a single individual, under which the company will issue 6,332,692 shares of common stock and a new $600,000 convertible promissory note. This transaction is in exchange for the surrender and cancellation of a previous $3,000,000 convertible promissory note. The new note bears interest at 10% per annum, payable semi-annually, and is convertible into common stock at an initial price of $0.01 per share, subject to adjustment. The principal amount of the new note is due on demand. No additional consideration was paid in connection with this exchange. The securities will be issued without registration under the Securities Act, relying on an exemption from registration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-124513), on December 22, 2025, and is solely responsible for the information contained therein.